B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
CLRB
Cellectar BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+80.5
Score
AI commentary
Primary company and SEC materials are constructive on clinical progress, CLOVER-WaM data, Phase 3 preparation, and the planned mid-2027 NDA. However, the packet provides no reliable post-release price reaction, analyst target revisions, options data, short-interest data, or social coverage. With low coverage and a highly binary development path, this remains a cautious monitoring thesis rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-23eventConfirmatory Phase 3 site activation and early-2027 dosingHigh impact
Cellectar initiated site-activation activities for the confirmatory iopofosine I 131 study in relapsed/refractory Waldenström macroglobulinemia; sites are expected to open in coming months and first dosing is planned for early 2027 [#SEC-8K-2026-08-13].
2026-11-23eventCLR 125 Phase 1b progress in triple-negative breast cancerHigh impact
The company initiated enrollment and dosed the first patients in its CLR 125 Phase 1b trial in refractory triple-negative breast cancer [#SEC-8K-2026-08-13]. Further enrollment or early clinical data could broaden the pipeline narrative, but the program remains early stage.
2027-08-25catalystClinical execution, financing, and dilution sensitivityHigh impact
The investment case remains vulnerable to trial delays, enrollment risk, regulatory setbacks, and future capital needs typical of a low-coverage development-stage biotech. The latest company update describes a strengthened balance sheet but does not eliminate long-term funding risk [#SEC-8K-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology